Neuroone Medical Technologies (NMTC) Stock
Small cap medical device company developing neurological treatments. Here's the price, business snapshot, and what's worth knowing about Neuroone Medical Technologies in October 2026.
NeuroOne Medical Technologies Corp (NMTC) is a small‑cap medical‑device company developing neuromodulation technologies aimed at treating neurological conditions such as chronic pain and movement disorders. With a market capitalisation around $41 million, the company is still at an early commercial and clinical stage, so investors should expect a focus on product development, regulatory milestones and clinical data rather than steady revenue. Key considerations include regulatory approvals, the strength of clinical evidence, reimbursement pathways and the potential for dilution if additional capital is required. Neuromodulation is a growing area with meaningful clinical need, but outcomes can be binary and timelines uncertain. This summary is educational and not personal advice — research the company’s filings, recent clinical updates and cash runway, and consider how a high‑volatility, speculative medical‑device stock fits within a diversified portfolio.
Neuroone Medical Technologies (NMTC) Stock Forecast
Analyst price target, next 12 months
$6.90
+516.1% vs today's $1.12
Price range over the last 12 months
Close to its 12-month low
Analysts covering Neuroone Medical Technologies have a consensus 12-month target of $6.90, above the current price of $1.12.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 2 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend purchasing NeuroOne's stock, predicting it could rise significantly.
Financial Health
NeuroOne is generating steady revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Neuromodulation focus
The company targets devices for neurological conditions, an area with clinical demand — though clinical and regulatory outcomes can be uncertain.
Catalysts to watch
Regulatory approvals, trial readouts and commercial partnerships could move the story; these are binary events that carry both upside and downside.
Capital and runway
As a small‑cap firm, funding needs and potential dilution are important to monitor; limited cash reserves can affect development timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
